Sarepta Therapeutics - SRPT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $163.94
  • Forecasted Upside: 28.95%
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$127.13
▼ -1.17 (-0.91%)

This chart shows the closing price for SRPT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sarepta Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SRPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SRPT

Analyst Price Target is $163.94
▲ +28.95% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Sarepta Therapeutics in the last 3 months. The average price target is $163.94, with a high forecast of $224.00 and a low forecast of $109.00. The average price target represents a 28.95% upside from the last price of $127.13.

This chart shows the closing price for SRPT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 14 polled investment analysts is to moderate buy stock in Sarepta Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/30/2022
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/28/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/29/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/27/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/25/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/23/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/23/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/20/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$166.00Low
5/17/2024MizuhoBoost TargetBuy ➝ Buy$145.00 ➝ $179.00Low
5/14/2024OppenheimerUpgradeMarket Perform ➝ Outperform$180.00Low
5/3/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$177.00 ➝ $175.00Low
5/2/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$128.00Low
5/2/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$166.00Low
3/1/2024UBS GroupBoost TargetBuy ➝ Buy$164.00 ➝ $167.00Low
2/29/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$128.00Low
2/29/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$151.00 ➝ $157.00Low
2/29/2024WedbushReiterated RatingOutperform$224.00Low
2/29/2024CitigroupBoost TargetBuy ➝ Buy$160.00 ➝ $172.00Low
2/29/2024BarclaysBoost TargetOverweight ➝ Overweight$141.00 ➝ $185.00Low
2/29/2024Needham & Company LLCLower TargetBuy ➝ Buy$169.00 ➝ $166.00Low
2/20/2024Evercore ISIBoost TargetIn-Line ➝ In-Line$108.00 ➝ $138.00Low
2/20/2024WedbushReiterated RatingOutperform ➝ Outperform$224.00Low
2/16/2024Needham & Company LLCBoost TargetBuy ➝ Buy$140.00 ➝ $169.00Low
2/14/2024MizuhoBoost TargetBuy ➝ Buy$130.00 ➝ $145.00Low
2/14/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$128.00Low
1/31/2024BMO Capital MarketsInitiated CoverageOutperform$170.00Low
1/29/2024WedbushReiterated RatingOutperform ➝ Outperform$224.00Low
1/29/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$140.00Low
1/25/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$155.00 ➝ $151.00Low
1/10/2024Needham & Company LLCBoost TargetBuy ➝ Buy$93.00 ➝ $140.00Low
1/9/2024WedbushReiterated RatingOutperform ➝ Outperform$224.00Low
12/13/2023CitigroupInitiated CoverageBuy$113.00Low
12/12/2023Deutsche Bank AktiengesellschaftInitiated CoverageBuy$109.00Low
11/21/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$148.00Low
11/21/2023WedbushInitiated CoverageOutperform$224.00Low
11/2/2023BarclaysLower TargetOverweight ➝ Overweight$193.00 ➝ $141.00N/A
10/31/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$211.00 ➝ $115.00Low
10/31/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$217.00 ➝ $148.00Low
10/31/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Neutral$166.00 ➝ $40.00Low
10/31/2023OppenheimerDowngradeOutperform ➝ Market PerformLow
10/31/2023Morgan StanleyLower TargetOverweight ➝ Overweight$183.00 ➝ $146.00Low
10/31/2023Needham & Company LLCLower TargetBuy ➝ Buy$185.00 ➝ $82.00Low
9/26/2023MizuhoReiterated RatingBuy ➝ Buy$160.00Low
8/3/2023Needham & Company LLCReiterated RatingBuy$185.00Low
8/3/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$183.00Low
8/3/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$221.00 ➝ $223.00Low
7/14/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$183.00Low
6/23/2023CitigroupLower Target$204.00 ➝ $161.00Low
6/23/2023JPMorgan Chase & Co.Lower Target$217.00 ➝ $213.00Low
6/23/2023Bank of AmericaBoost Target$176.00 ➝ $186.00Low
6/23/2023BarclaysBoost Target$170.00 ➝ $193.00Low
5/30/2023Evercore ISILower Target$173.00 ➝ $151.00Low
5/24/2023Credit Suisse GroupLower Target$151.00 ➝ $141.00Low
5/16/2023Royal Bank of CanadaBoost Target$197.00 ➝ $218.00Low
5/15/2023Bank of AmericaBoost Target$164.00 ➝ $176.00Low
5/15/2023UBS GroupBoost Target$160.00 ➝ $173.00Low
5/15/2023Credit Suisse GroupBoost Target$138.00 ➝ $151.00Low
5/3/2023Cantor FitzgeraldLower Target$165.00 ➝ $158.00Low
4/26/2023Sumitomo Mitsui Financial GroupInitiated CoverageOutperform$185.00Low
4/14/2023MizuhoReiterated RatingBuy$160.00Low
4/12/2023Morgan StanleyLower Target$187.00 ➝ $183.00Low
4/4/2023CitigroupInitiated CoverageBuy ➝ Buy$179.00Low
3/22/2023TD CowenBoost TargetOutperform$125.00 ➝ $175.00Low
3/17/2023Royal Bank of CanadaLower TargetOutperform$226.00 ➝ $200.00Low
3/17/2023MizuhoReiterated RatingBuy$160.00Low
3/17/2023Cantor FitzgeraldLower Target$178.00 ➝ $165.00Low
3/17/2023Credit Suisse GroupLower TargetNeutral$144.00 ➝ $139.00Low
3/17/2023Needham & Company LLCLower TargetBuy$200.00 ➝ $160.00Low
3/9/2023OppenheimerLower TargetOutperform$180.00 ➝ $150.00Low
3/3/2023JPMorgan Chase & Co.Boost TargetOverweight$153.00 ➝ $206.00Low
3/1/2023Needham & Company LLCBoost TargetBuy$160.00 ➝ $200.00Low
3/1/2023The Goldman Sachs GroupBoost TargetBuy$171.00 ➝ $190.00Low
3/1/2023Royal Bank of CanadaBoost TargetOutperform$195.00 ➝ $226.00Low
3/1/2023OppenheimerBoost TargetOutperform$150.00 ➝ $180.00Low
3/1/2023Credit Suisse GroupBoost TargetNeutral$137.00 ➝ $144.00Low
3/1/2023Robert W. BairdBoost TargetOutperform$152.00 ➝ $202.00Low
3/1/2023BarclaysBoost Target$149.00 ➝ $170.00Low
3/1/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$141.00 ➝ $187.00Low
2/15/2023Credit Suisse GroupBoost TargetNeutral$114.00 ➝ $137.00Low
1/20/2023SVB LeerinkReiterated RatingOutperform$160.00Low
1/11/2023CowenBoost Target$114.00 ➝ $125.00Low
1/10/2023Needham & Company LLCBoost TargetBuy$158.00 ➝ $160.00Low
1/10/2023Credit Suisse GroupBoost TargetNeutral$101.00 ➝ $114.00Low
12/22/2022BTIG ResearchBoost TargetBuy$125.00 ➝ $160.00Low
12/16/2022UBS GroupUpgradeNeutral ➝ Buy$100.00 ➝ $158.00Low
12/13/2022Cantor FitzgeraldBoost Target$150.00 ➝ $174.00Low
11/3/2022Royal Bank of CanadaLower TargetOutperform$193.00 ➝ $190.00Low
11/3/2022The Goldman Sachs GroupBoost TargetBuy$152.00 ➝ $171.00Low
11/3/2022Credit Suisse GroupBoost TargetNeutral$93.00 ➝ $101.00Low
11/3/2022Robert W. BairdBoost Target$110.00 ➝ $152.00Low
11/3/2022Needham & Company LLCLower TargetBuy$162.00 ➝ $158.00Low
10/17/2022SVB LeerinkBoost TargetOutperform$126.00 ➝ $145.00Low
10/13/2022Morgan StanleyBoost TargetEqual Weight$135.00 ➝ $141.00Low
9/8/2022Morgan StanleyBoost TargetEqual Weight$100.00 ➝ $135.00Low
8/9/2022Royal Bank of CanadaBoost TargetOutperform$160.00 ➝ $182.00Low
8/3/2022Royal Bank of CanadaBoost TargetOutperform$156.00 ➝ $160.00N/A
8/3/2022GuggenheimBoost Target$100.00 ➝ $122.00Low
8/3/2022Morgan StanleyBoost TargetEqual Weight$80.00 ➝ $100.00Low
8/3/2022Credit Suisse GroupBoost TargetNeutral$90.00 ➝ $93.00Low
8/3/2022BarclaysBoost Target$104.00 ➝ $125.00Low
8/3/2022OppenheimerBoost Target$125.00 ➝ $150.00Low
7/29/2022Needham & Company LLCBoost TargetBuy$150.00 ➝ $162.00Low
6/24/2022Cantor FitzgeraldLower TargetOverweight$140.00 ➝ $128.00Low
6/24/2022Credit Suisse GroupLower TargetNeutral$95.00 ➝ $90.00Low
5/24/2022The Goldman Sachs GroupLower TargetBuy$181.00 ➝ $155.00Medium
5/19/2022Morgan StanleyLower TargetEqual Weight$77.00 ➝ $74.00Low
4/12/2022Morgan StanleyLower TargetEqual Weight$80.00 ➝ $77.00Low
3/7/2022Morgan StanleyBoost TargetEqual Weight$71.00 ➝ $80.00High
3/2/2022BarclaysLower Target$125.00 ➝ $104.00Medium
3/2/2022Royal Bank of CanadaBoost TargetOutperform$145.00 ➝ $150.00High
2/1/2022Morgan StanleyLower TargetEqual Weight$92.00 ➝ $71.00Medium
1/18/2022Morgan StanleyBoost TargetEqual Weight$90.00 ➝ $92.00Low
1/11/2022Needham & Company LLCReiterated RatingBuy$150.00Medium
1/5/2022Needham & Company LLCLower TargetBuy$157.00 ➝ $150.00High
12/9/2021OppenheimerUpgradeMarket Perform ➝ Outperform$125.00Medium
11/5/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$88.00 ➝ $130.00Medium
11/4/2021Cantor FitzgeraldBoost TargetOverweight$128.00 ➝ $140.00High
11/4/2021Royal Bank of CanadaLower TargetOutperform$148.00 ➝ $145.00High
11/4/2021Needham & Company LLCLower TargetBuy$166.00 ➝ $157.00High
10/15/2021Berenberg BankReiterated RatingHold$90.00High
10/12/2021Credit Suisse GroupBoost TargetNeutral$75.00 ➝ $100.00High
10/12/2021SVB LeerinkReiterated RatingBuyHigh
10/12/2021Needham & Company LLCReiterated RatingBuyHigh
10/12/2021BTIG ResearchBoost TargetBuy$110.00 ➝ $125.00High
10/7/2021Robert W. BairdInitiated CoverageBuy$110.00Medium
9/15/2021GuggenheimUpgradeNeutral ➝ BuyHigh
8/16/2021Morgan StanleyLower TargetEqual Weight$93.00 ➝ $90.00High
8/5/2021Credit Suisse GroupBoost TargetNeutral$72.00 ➝ $75.00High
8/5/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$92.00 ➝ $87.00High
7/1/2021Berenberg BankInitiated CoverageHold$85.00Medium
6/14/2021BTIG ResearchInitiated CoverageBuy$110.00High
5/3/2021Needham & Company LLCInitiated CoverageBuy$166.00High
4/19/2021Morgan StanleyLower TargetEqual Weight$95.00 ➝ $93.00Low
4/16/2021William BlairReiterated RatingBuyLow
3/21/2021SVB LeerinkReiterated RatingBuyLow
3/2/2021Royal Bank of CanadaLower TargetOutperform$143.00 ➝ $132.00High
3/2/2021Needham & Company LLCReiterated RatingBuy$166.00High
3/2/2021SVB LeerinkBoost TargetOutperform$125.00 ➝ $126.00High
3/2/2021Piper SandlerLower TargetNeutral$140.00 ➝ $130.00High
2/26/2021MizuhoBoost TargetBuy$158.00 ➝ $160.00High
1/12/2021Smith Barney CitigroupDowngradeBuy ➝ NeutralHigh
1/11/2021UBS GroupDowngradeBuy ➝ NeutralHigh
1/8/2021OppenheimerReiterated RatingHold ➝ NeutralHigh
1/8/2021Credit Suisse GroupLower TargetNeutral$156.00 ➝ $73.00N/A
1/8/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Underweight$96.00N/A
1/8/2021Robert W. BairdLower TargetOutperform$223.00 ➝ $110.00N/A
1/8/2021CowenLower TargetOutperform$213.00 ➝ $114.00N/A
1/8/2021Needham & Company LLCLower TargetBuy$182.00 ➝ $166.00N/A
1/8/2021BarclaysLower TargetPositive ➝ Overweight$192.00 ➝ $125.00N/A
1/8/2021Cantor FitzgeraldLower TargetOverweight$217.00 ➝ $128.00N/A
1/8/2021Royal Bank of CanadaLower TargetOutperform$200.00 ➝ $143.00N/A
1/8/2021MizuhoLower TargetBuy$204.00 ➝ $158.00N/A
1/8/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$182.00 ➝ $95.00N/A
1/8/2021Raymond JamesDowngradeOutperform ➝ Market PerformN/A
1/8/2021SVB LeerinkLower TargetOutperform$197.00 ➝ $125.00N/A
1/4/2021Piper SandlerBoost TargetOverweight$200.00 ➝ $240.00N/A
12/14/2020Smith Barney CitigroupBoost Target$190.00 ➝ $215.00Low
12/14/2020Credit Suisse GroupLower TargetNeutral$162.00 ➝ $156.00Medium
12/8/2020MizuhoBoost TargetBuy$192.00 ➝ $204.00High
11/11/2020Berenberg BankInitiated CoverageHold$140.00Medium
11/6/2020Credit Suisse GroupLower TargetNeutral$167.00 ➝ $162.00High
11/6/2020SVB LeerinkLower TargetOutperform$214.00 ➝ $197.00High
10/28/2020UBS GroupInitiated CoverageBuy$212.00Low
10/11/2020Royal Bank of CanadaReiterated RatingBuyLow
9/15/2020CitigroupBoost TargetBuy$177.00 ➝ $190.00Medium
8/31/2020HC WainwrightLower TargetBuy$260.00 ➝ $221.00Low
8/24/2020Raymond JamesInitiated CoverageOutperform$200.00High
8/21/2020Bank of AmericaLower TargetBuy$190.00 ➝ $189.00Medium
8/20/2020Credit Suisse GroupDowngradeOutperform ➝ Neutral$185.00 ➝ $167.00High
8/10/2020Morgan StanleyBoost TargetOverweight$172.00 ➝ $182.00Low
8/4/2020Piper SandlerLower TargetOverweight$206.00 ➝ $200.00Low
8/3/2020Credit Suisse GroupReiterated RatingBuyLow
6/22/2020JPMorgan Chase & Co.Boost TargetOverweight$160.00 ➝ $190.00Low
6/16/2020HC WainwrightReiterated RatingBuy$260.00Medium
6/10/2020Bank of AmericaReiterated RatingBuy$180.00High
6/8/2020HC WainwrightReiterated RatingBuy$260.00High
6/8/2020Robert W. BairdReiterated RatingBuy$192.00High
5/17/2020NomuraReiterated RatingBuy$230.00High
5/15/2020JPMorgan Chase & Co.Reiterated RatingBuyHigh
5/15/2020Robert W. BairdReiterated RatingBuy$192.00High
5/15/2020HC WainwrightReiterated RatingBuy$260.00High
5/7/2020Needham & Company LLCInitiated CoverageBuy$182.00High
5/7/2020Credit Suisse GroupReiterated RatingBuy$185.00High
5/7/2020OppenheimerReiterated RatingHoldHigh
5/6/2020Royal Bank of CanadaReiterated RatingBuy$182.00Low
4/30/2020MizuhoReiterated RatingBuy$183.00Low
4/15/2020Morgan StanleyLower TargetOverweight$173.00 ➝ $172.00Low
3/30/2020MizuhoInitiated CoverageBuy$183.00High
2/28/2020JPMorgan Chase & Co.Lower TargetOverweight$172.00 ➝ $160.00High
2/27/2020Cantor FitzgeraldReiterated RatingOverweight$211.00 ➝ $217.00High
2/27/2020JMP SecuritiesLower TargetOutperform$280.00 ➝ $217.00High
2/25/2020Nomura SecuritiesReiterated RatingBuy$230.00High
1/23/2020SVB LeerinkReiterated RatingBuy$216.00Low
1/14/2020Credit Suisse GroupReiterated RatingBuy$185.00Low
1/14/2020CowenReiterated RatingBuy$213.00High
1/7/2020Bank of AmericaReiterated RatingBuy$187.00High
12/30/2019OppenheimerReiterated RatingHoldLow
12/26/2019CitigroupReiterated RatingBuy$177.00Low
12/25/2019Nomura SecuritiesReiterated RatingBuy$230.00Low
12/24/2019The Goldman Sachs GroupReiterated RatingBuy$180.00Low
12/24/2019Morgan StanleyBoost TargetOverweight$160.00 ➝ $173.00Low
12/24/2019Credit Suisse GroupReiterated RatingOverweight ➝ Outperform$190.00 ➝ $185.00Low
12/23/2019Piper Sandler CompaniesReiterated RatingBuy$210.00N/A
12/23/2019Royal Bank of CanadaLower TargetOutperform$215.00 ➝ $200.00Medium
12/20/2019Robert W. BairdBoost TargetOutperform$181.00 ➝ $192.00Low
12/18/2019Nomura SecuritiesReiterated RatingBuy$230.00Low
12/17/2019CitigroupBoost TargetBuy$167.00 ➝ $177.00Low
12/15/2019CowenInitiated CoverageBuy$213.00Medium
12/15/2019BarclaysReiterated RatingBuy$202.00Medium
12/13/2019HC WainwrightBoost Target$160.00 ➝ $260.00Low
12/13/2019Cantor FitzgeraldBoost TargetOverweight$175.00 ➝ $211.00High
12/13/2019SVB LeerinkReiterated RatingOutperform$186.00 ➝ $216.00Medium
12/13/2019Piper Sandler CompaniesReiterated RatingBuy$185.00 ➝ $210.00High
12/13/2019Credit Suisse GroupBoost TargetOutperform$185.00 ➝ $190.00High
12/13/2019Janney Montgomery ScottBoost TargetBuy$160.00 ➝ $175.00High
12/13/2019Royal Bank of CanadaReiterated RatingOutperform$215.00High
11/18/2019CitigroupLower TargetBuy ➝ Positive$180.00 ➝ $167.00Low
11/8/2019Credit Suisse GroupLower TargetOutperform$201.00 ➝ $185.00High
11/1/2019GuggenheimInitiated CoverageBuy$183.00High
10/11/2019Morgan StanleyLower TargetOverweight$220.00 ➝ $160.00Low
10/8/2019OppenheimerReiterated RatingHoldLow
9/27/2019Piper Sandler CompaniesSet TargetBuy$185.00Low
9/27/2019CitigroupLower TargetBuy$185.00 ➝ $180.00Medium
9/24/2019Royal Bank of CanadaSet TargetBuy$204.00High
9/13/2019HC WainwrightSet TargetBuy$160.00Low
8/21/2019Needham & Company LLCLower TargetBuy$196.00 ➝ $170.00Low
8/20/2019Royal Bank of CanadaLower TargetOutperform$204.00Low
8/20/2019Cantor FitzgeraldLower TargetOverweight$231.00 ➝ $175.00Low
8/20/2019Robert W. BairdLower TargetOutperform$202.00 ➝ $181.00High
8/20/2019Bank of AmericaLower TargetBuy$200.00 ➝ $189.00High
8/20/2019Credit Suisse GroupLower TargetOutperform$207.00 ➝ $201.00High
8/20/2019Janney Montgomery ScottLower TargetBuy$200.00 ➝ $175.00High
8/20/2019HC WainwrightReiterated RatingBuy$160.00 ➝ $267.00High
8/20/2019Piper Sandler CompaniesLower TargetOverweight$208.00 ➝ $185.00High
8/9/2019William BlairReiterated RatingBuyLow
8/8/2019Evercore ISIReiterated RatingBuy$200.00High
7/9/2019Morgan StanleyBoost TargetOverweight ➝ Overweight$165.00 ➝ $220.00Medium
7/1/2019Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$188.00 ➝ $220.00Low
6/17/2019HC WainwrightSet TargetBuy$267.00Low
(Data available from 5/23/2019 forward)

News Sentiment Rating

0.71 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/26/2023
  • 10 very positive mentions
  • 22 positive mentions
  • 6 negative mentions
  • 6 very negative mentions
11/25/2023
  • 13 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/25/2023
  • 26 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
1/24/2024
  • 31 very positive mentions
  • 40 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
2/23/2024
  • 21 very positive mentions
  • 25 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/24/2024
  • 12 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
4/23/2024
  • 28 very positive mentions
  • 35 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
5/23/2024

Current Sentiment

  • 28 very positive mentions
  • 35 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Sarepta Therapeutics logo
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $127.13
Low: $125.50
High: $129.84

50 Day Range

MA: $126.95
Low: $115.62
High: $136.04

52 Week Range

Now: $127.13
Low: $55.25
High: $146.68

Volume

847,555 shs

Average Volume

1,015,283 shs

Market Capitalization

$12.02 billion

P/E Ratio

1,155.73

Dividend Yield

N/A

Beta

0.95

Frequently Asked Questions

What sell-side analysts currently cover shares of Sarepta Therapeutics?

The following sell-side analysts have issued stock ratings on Sarepta Therapeutics in the last year: Bank of America Co., Barclays PLC, BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Evercore ISI, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Royal Bank of Canada, StockNews.com, TheStreet, UBS Group AG, and Wedbush.
View the latest analyst ratings for SRPT.

What is the current price target for Sarepta Therapeutics?

16 Wall Street analysts have set twelve-month price targets for Sarepta Therapeutics in the last year. Their average twelve-month price target is $163.94, suggesting a possible upside of 30.0%. Wedbush has the highest price target set, predicting SRPT will reach $224.00 in the next twelve months. Deutsche Bank Aktiengesellschaft has the lowest price target set, forecasting a price of $109.00 for Sarepta Therapeutics in the next year.
View the latest price targets for SRPT.

What is the current consensus analyst rating for Sarepta Therapeutics?

Sarepta Therapeutics currently has 2 hold ratings and 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SRPT.

What other companies compete with Sarepta Therapeutics?

How do I contact Sarepta Therapeutics' investor relations team?

Sarepta Therapeutics' physical mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company's listed phone number is (617) 274-4000 and its investor relations email address is [email protected]. The official website for Sarepta Therapeutics is www.sareptatherapeutics.com. Learn More about contacing Sarepta Therapeutics investor relations.